NGLFINE2,701.00

NGL Fine-Chem Limited

· Pharma & Health
₹ CrorePeersSYNCOMFJAGSNPHARMHESTERBIOAMRUTANJANWINDLASINDOCOSAIPARENTMcap ₹1,669 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity15.737.4814.6214.62
Return on Assets11.624.878.828.82
Return on Capital Employed15.486.8113.4313.43
Return on Invested Capital13.115.5310.1912.11
Margins
EBITDA Margin15.739.2014.5115.70
Operating Margin12.295.8210.6010.60
Incremental Operating Margin-68.3523.88
Pretax Margin16.077.5312.6514.16
Net Income Margin12.205.749.6110.67
FCF Margin-2.38-25.78-9.29-9.29
Additional
Effective Tax Rate24.0723.7824.0524.66
Dvd Payout Ratio2.625.122.25
Sustainable Growth Rate15.327.1014.2914.62
Incremental Operating Margin %-68.3523.8829.80
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.